StockData
TG Therapeutics, Inc. logo

TG Therapeutics, Inc. (TGTX) stock

TGTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 9/3010% above fair value
$66.12+3.41 (+5.44%)

Close on Nov 18, 2026Market cap $10.12BP/E 24.1Yield –

TG Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

TG Therapeutics's operating income for the twelve months ending Jun 30, 2026 was $136.33M, up 58.8% year over year. For fiscal 2025 it was $123.32M, up 194.1% from the year before. The highest annual figure on record is $123.32M in fiscal 2025.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025$123.32M+194.1%
FY2024Dec 31, 2024$41.93M+103.2%
FY2023Dec 31, 2023$20.63M–
FY2022Dec 31, 2022-$218.32M–
FY2021Dec 31, 2021-$344.77M–
FY2020Dec 31, 2020-$273.59M–
FY2019Dec 31, 2019-$169.06M–
FY2018Dec 31, 2018-$174.40M–
FY2017Dec 31, 2017-$118.71M–
FY2016Dec 31, 2016-$78.97M–
FY2015Dec 31, 2015-$63.18M–
FY2014Dec 31, 2014-$55.72M–
FY2013Dec 31, 2013-$22.97M–
FY2012Dec 31, 2012-$26.90M–
FY2011Dec 31, 2011-$881.97K–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$21.67M-37.8%
Q1 FY2026Mar 31, 2026$34.80M+303.6%
Q4 FY2025Dec 31, 2025$50.49M+68.6%
Q3 FY2025Sep 30, 2025$29.37M+136.2%
Q2 FY2025Jun 30, 2025$34.84M+295.2%
Q1 FY2025Mar 31, 2025$8.62M–
Q4 FY2024Dec 31, 2024$29.95M–
Q3 FY2024Sep 30, 2024$12.43M-89.2%
Q2 FY2024Jun 30, 2024$8.82M–
Q1 FY2024Mar 31, 2024-$9.27M–
Q4 FY2023Dec 31, 2023-$12.49M–
Q3 FY2023Sep 30, 2023$114.78M–
Q2 FY2023Jun 30, 2023-$44.67M–
Q1 FY2023Mar 31, 2023-$36.99M–
Q4 FY2022Dec 31, 2022-$77.54M–
Q3 FY2022Sep 30, 2022-$34.96M–
Q2 FY2022Jun 30, 2022-$38.94M–
Q1 FY2022Mar 31, 2022-$66.87M–
Q4 FY2021Dec 31, 2021-$92.95M–
Q3 FY2021Sep 30, 2021-$85.13M–
Q2 FY2021Jun 30, 2021-$77.49M–
Q1 FY2021Mar 31, 2021-$89.20M–
Q4 FY2020Dec 31, 2020-$86.78M–
Q3 FY2020Sep 30, 2020-$85.72M–
Q2 FY2020Jun 30, 2020-$50.85M–
Q1 FY2020Mar 31, 2020-$50.25M–
Q4 FY2019Dec 31, 2019-$37.96M–
Q3 FY2019Sep 30, 2019-$60.86M–
Q2 FY2019Jun 30, 2019-$35.54M-180.2%
Q1 FY2019Mar 31, 2019-$34.69M–
Q4 FY2018Dec 31, 2018-$54.15M–
Q3 FY2018Sep 30, 2018-$34.33M–
Q2 FY2018Jun 30, 2018$44.35M–
Q1 FY2018Mar 31, 2018-$41.58M–
Q4 FY2017Dec 31, 2017-$31.04M–
Q3 FY2017Sep 30, 2017-$31.59M–
Q2 FY2017Jun 30, 2017-$28.43M–
Q1 FY2017Mar 31, 2017-$27.67M–
Q4 FY2016Dec 31, 2016-$24.03M–
Q3 FY2016Sep 30, 2016-$24.93M–

More TG Therapeutics figures

See a number that looks wrong?